SCHEMBL5136707

SCHEMBL5136707

CCCCN(Cc1ccc(O)c(OCC)c1)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
C5AR1 P21730 1/20 0.41
DRD1 P21728 4/20 0.36
DRD4 P21917 4/20 0.36
DRD3 P35462 4/20 0.36
DRD2 P14416 2/20 0.36
DRD5 P21918 2/20 0.36
ATP4A P20648 2/20 0.35
ATP4B P51164 2/20 0.35
MMP1 P03956 1/20 0.35
MMP13 P45452 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CRHR1 P34998 2/20 0.34
MAPK14 Q16539 1/20 0.34
SSTR5 P35346 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070033 0.93 C5AR1 (0.41) C5AR1DRD1DRD4DRD3DRD2
SCHEMBL5072402 0.93 MAPT (0.43) MAPTC5AR1ATP4AATP4BMEN1
SCHEMBL5075007 0.92 MAPT (0.44) MAPTC5AR1DRD1DRD4DRD3
SCHEMBL5134693 0.89 C5AR1 (0.45) C5AR1ATP4AATP4BMMP1MMP13
SCHEMBL5134767 0.88 MAPT (0.40) MAPTC5AR1DRD3DRD2MEN1
SCHEMBL5137337 0.88 C5AR1 (0.41) C5AR1DRD1DRD4DRD3DRD2
SCHEMBL648771 0.88 C5AR1 (0.45) C5AR1SMN1; SMN2MEN1KMT2A
SCHEMBL651447 0.87 C5AR1 (0.46) MAPTC5AR1ATP4AATP4BSMN1; SMN2
SCHEMBL5136877 0.87 C5AR1 (0.43) C5AR1DRD1DRD4DRD3DRD2
SCHEMBL5135240 0.86 C5AR1 (0.42) C5AR1ATP4AATP4BMMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed